000096159 001__ 96159
000096159 005__ 20210902121851.0
000096159 0247_ $$2doi$$a10.3389/fonc.2020.568939
000096159 0248_ $$2sideral$$a120722
000096159 037__ $$aART-2020-120722
000096159 041__ $$aeng
000096159 100__ $$aOcáriz-Díez, M.
000096159 245__ $$aMicrobiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy
000096159 260__ $$c2020
000096159 5060_ $$aAccess copy available to the general public$$fUnrestricted
000096159 5203_ $$aThe advances in molecular biology and the emergence of Next Generation Sequencing (NGS) have revealed that microbiome composition is closely related with health and disease, including cancer. This relationship affects different levels of cancer such as development, progression, and response to treatment including immunotherapy. The efficacy of immune checkpoint inhibitors (ICIs) may be influenced by the concomitant use of antibiotics before, during or shortly after treatment with ICIs. Nevertheless, the linking mechanism between microbiote, host immunity and cancer is not clear and the role of microbiota manipulation and analyses in cancer management has not been clinically validated yet. Regarding the use of microbiome as biomarker to predict ICI efficacy it has been recently shown that the use of biochemical serum markers to monitor intestinal permeability and loss of barrier integrity, like citrulline, could be useful to monitor microbiota changes and predict ICI efficacy. There are still many unknowns about the role of these components, their relationship with the microbiota, with the use of antibiotics and the response to immunotherapy. The next challenge in microbiome research will be to identify individual microbial species that causally affect lung cancer phenotypes and response to ICI and disentangle the underlying mechanisms. Thus, further analyses in patients with lung cancer receiving treatment with ICIs and its correlation with the composition of the microbiota in different organs including the respiratory tract, peripheral blood and intestinal tract could be useful to predict the efficacy of ICIs and its modulation with antibiotic use.
000096159 536__ $$9info:eu-repo/grantAgreement/ES/DGA-FEDER/B29-17R$$9info:eu-repo/grantAgreement/ES/MCIU-AEI/SAF2017-83120-C2-1-R
000096159 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000096159 590__ $$a6.244$$b2020
000096159 591__ $$aONCOLOGY$$b62 / 242 = 0.256$$c2020$$dQ2$$eT1
000096159 592__ $$a1.834$$b2020
000096159 593__ $$aOncology$$c2020$$dQ1
000096159 593__ $$aCancer Research$$c2020$$dQ1
000096159 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion
000096159 700__ $$aCruellas, M.
000096159 700__ $$aGascón, M.
000096159 700__ $$aLastra, R.
000096159 700__ $$0(orcid)0000-0003-3043-147X$$aMartínez-Lostao, L.$$uUniversidad de Zaragoza
000096159 700__ $$0(orcid)0000-0002-3888-7036$$aRamírez-Labrada, A.
000096159 700__ $$0(orcid)0000-0002-9600-8116$$aPaño, J.R.$$uUniversidad de Zaragoza
000096159 700__ $$aSesma, A.
000096159 700__ $$0(orcid)0000-0003-3387-0558$$aTorres, I.$$uUniversidad de Zaragoza
000096159 700__ $$aYubero, A.
000096159 700__ $$0(orcid)0000-0003-0154-0730$$aPardo, J.$$uUniversidad de Zaragoza
000096159 700__ $$aIsla, D.
000096159 700__ $$aGálvez, E.M.
000096159 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000096159 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000096159 773__ $$g10 (2020), 568939 [8 pp]$$pFront. oncol.$$tFrontiers in Oncology$$x2234-943X
000096159 8564_ $$s135913$$uhttps://zaguan.unizar.es/record/96159/files/texto_completo.pdf$$yVersión publicada
000096159 8564_ $$s29282$$uhttps://zaguan.unizar.es/record/96159/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000096159 909CO $$ooai:zaguan.unizar.es:96159$$particulos$$pdriver
000096159 951__ $$a2021-09-02-10:29:54
000096159 980__ $$aARTICLE